MARKET

EXEL

EXEL

Exelixis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

24.94
+0.76
+3.14%
After Hours: 25.25 +0.31 +1.24% 19:53 07/10 EDT
OPEN
24.29
PREV CLOSE
24.18
HIGH
25.43
LOW
24.26
VOLUME
3.66M
TURNOVER
--
52 WEEK HIGH
27.80
52 WEEK LOW
13.67
MARKET CAP
7.65B
P/E (TTM)
26.76
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EXEL stock price target is 29.85 with a high estimate of 40.00 and a low estimate of 21.00.

EPS

EXEL News

More
2 Stocks to Buy if You're Worried About Another Market Crash
Motley Fool · 16h ago
Got $3,000? 3 Growth Stocks You Won't Regret Buying
Motley Fool · 18h ago
XBI: Not Everybody Can Be A Hero
Seeking Alpha - Article · 2d ago
5 Booming Biotech Stocks to Buy
Kiplinger · 07/03 17:36
Revance Positive Data And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 07/03 06:07
Ipsen teams up for cabozantinib combo study in lung and prostate cancer
Seeking Alpha - Article · 07/02 10:46
Exelixis launches late-stage study of cabozantinib combo in prostate cancer
Seeking Alpha - Article · 06/30 14:36
Exelixis Announces Initiation of CONTACT-02 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Castration-Resistant Prostate Cancer
Business Wire · 06/30 13:00

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About EXEL

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.
More

Webull offers kinds of Exelixis, Inc. stock information, including NASDAQ:EXEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXEL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EXEL stock methods without spending real money on the virtual paper trading platform.